
5-Hydroxytryptophan (5-HTP) is the immediate biosynthetic precursor to serotonin (5-hydroxytryptamine, 5-HT) and an intermediate in the metabolic pathway from tryptophan to melatonin. It is naturally produced in the body from L-tryptophan via the enzyme tryptophan hydroxylase, and is commercially derived primarily from the seeds of the African plant Griffonia simplicifolia. As a supplement, 5-HTP is used for mood enhancement, anxiety reduction, sleep improvement, and appetite suppression, with a mechanism distinct from pharmaceutical serotonergic agents — it provides serotonin's direct biochemical precursor rather than modulating its reuptake or synthesis enzymes.
5-HTP crosses the blood-brain barrier readily and is decarboxylated to serotonin within neurons and peripheral tissues by aromatic L-amino acid decarboxylase (AAAD). Unlike L-tryptophan, 5-HTP bypasses the rate-limiting tryptophan hydroxylase step and thus more directly and reliably increases serotonin production. This efficiency makes it a popular supplement for conditions associated with low serotonin tone, including depression, anxiety, insomnia, fibromyalgia, and compulsive overeating. Clinical trials have demonstrated efficacy comparable to some pharmaceutical antidepressants in mild-to-moderate depression, though study quality and sample sizes limit strong conclusions.
The most critical safety consideration for 5-HTP is its potential to cause serotonin syndrome when combined with serotonergic medications or drugs. Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity, characterized by agitation, hyperreflexia, hyperthermia, and in severe cases, seizures and cardiovascular collapse. Combinations of 5-HTP with MAOIs, SSRIs, SNRIs, tramadol, triptans, lithium, or psychedelic tryptamines carry meaningful risk of serotonin syndrome and should be either avoided entirely or managed only under medical supervision. This interaction profile must be understood before use.